Jennifer Pizzano

1.0k total citations
19 papers, 558 citations indexed

About

Jennifer Pizzano is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jennifer Pizzano has authored 19 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Jennifer Pizzano's work include Protein Degradation and Inhibitors (16 papers), Peptidase Inhibition and Analysis (7 papers) and Prostate Cancer Treatment and Research (6 papers). Jennifer Pizzano is often cited by papers focused on Protein Degradation and Inhibitors (16 papers), Peptidase Inhibition and Analysis (7 papers) and Prostate Cancer Treatment and Research (6 papers). Jennifer Pizzano collaborates with scholars based in United States and France. Jennifer Pizzano's co-authors include Ryan R. Willard, John Houston, I Taylor, Mark Bookbinder, Lawrence B. Snyder, Andrew P. Crew, Craig M. Crews, Taavi K. Neklesa, Nicholas Vitale and Jennifer Macaluso and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Jennifer Pizzano

17 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer Pizzano United States	10	473	265	143	68	38	19	558
Renqi Xu United States	7	550 1.2×	388 1.5×	166 1.2×	32 0.5×	12 0.3×	9	727
Gary Wilkinson United Kingdom	10	327 0.7×	179 0.7×	55 0.4×	78 1.1×	23 0.6×	23	546
Mark N. Ho United States	3	494 1.0×	220 0.8×	254 1.8×	8 0.1×	12 0.3×	5	608
Justine Meiller Ireland	11	185 0.4×	123 0.5×	94 0.7×	17 0.3×	20 0.5×	24	302
Alicja Puszkiel France	10	106 0.2×	134 0.5×	12 0.1×	50 0.7×	38 1.0×	29	304
Lipeng Dai United States	7	227 0.5×	116 0.4×	55 0.4×	39 0.6×	13 0.3×	8	329
Charles F. McHugh United States	8	320 0.7×	59 0.2×	122 0.9×	67 1.0×	12 0.3×	13	409
Jennifer S. Hackbarth United States	10	267 0.6×	137 0.5×	41 0.3×	42 0.6×	11 0.3×	10	391
Aakanksha Khandelwal United States	11	276 0.6×	81 0.3×	17 0.1×	127 1.9×	104 2.7×	14	488
Jinchan He China	9	295 0.6×	108 0.4×	11 0.1×	44 0.6×	33 0.9×	10	352

Countries citing papers authored by Jennifer Pizzano

Since Specialization

Citations

This map shows the geographic impact of Jennifer Pizzano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Pizzano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Pizzano more than expected).

Fields of papers citing papers by Jennifer Pizzano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Pizzano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Pizzano. The network helps show where Jennifer Pizzano may publish in the future.

Co-authorship network of co-authors of Jennifer Pizzano

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Pizzano. A scholar is included among the top collaborators of Jennifer Pizzano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Pizzano. Jennifer Pizzano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

DeCarr, Lynn B., Samantha L. Eaton, Deborah Witt Sherman, et al.. (2025). ABCL-796: ARV-393, a PROTAC BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors (SMIs) Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma (DLBCL) Models. Clinical Lymphoma Myeloma & Leukemia. 25. S760–S760.

DeCarr, Lynn B., Elizabeth Bortolon, Mark Bookbinder, et al.. (2025). Abstract 1655: ARV-393, a PROTAC B-cell lymphoma 6 (BCL6) degrader, combined with biologics or small molecule inhibitors (SMIs) induces tumor regressions in diffuse large B-cell lymphoma (DLBCL) models. Cancer Research. 85(8_Supplement_1). 1655–1655. 1 indexed citations

Smith, Katie, Jennifer Pizzano, Mark Bookbinder, et al.. (2025). Abstract B107: Preclinical activity of ARV-806, a PROTAC KRAS G12D degrader. Molecular Cancer Therapeutics. 24(10_Supplement). B107–B107.

Snyder, Lawrence B., Taavi K. Neklesa, Ryan R. Willard, et al.. (2024). Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. Molecular Cancer Therapeutics. 24(4). 511–522. 24 indexed citations

Zhang, Donglu, Bin Ma, Peter S. Dragovich, et al.. (2024). Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs. SHILAP Revista de lepidopterología. 4(1). 87–87. 8 indexed citations

Levy, Elizabeth S., An D. Nguyen, Donglu Zhang, et al.. (2023). Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs. Pharmaceutics. 15(8). 2098–2098. 12 indexed citations

Wu, Wendy, Monica Andreoli, Elizabeth Bortolon, et al.. (2023). Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader. Cancer Research. 83(7_Supplement). 432–432. 3 indexed citations

Snyder, Larry, Taavi K. Neklesa, Xin Chen, et al.. (2023). Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 83(7_Supplement). ND03–ND03. 12 indexed citations

Bortolon, Elizabeth, et al.. (2023). Abstract 3075: Enhanced efficacy of ARV-471, a novel PROTAC® estrogen receptor degrader, in combination with targeted agents in estrogen receptor-positive (ER+) breast cancer models. Cancer Research. 83(7_Supplement). 3075–3075. 4 indexed citations

10.

Smith, Kathryn E., Peter T. Nower, Jennifer Pizzano, et al.. (2023). Abstract PR09: KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models. Molecular Cancer Research. 21(5_Supplement). PR09–PR09. 2 indexed citations

11.

Snyder, Lawrence B., Taavi K. Neklesa, Xin Chen, et al.. (2021). Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 81(13_Supplement). 43–43. 49 indexed citations

12.

Snyder, Lawrence B., John J. Flanagan, Yimin Qian, et al.. (2021). Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer. Cancer Research. 81(13_Supplement). 44–44. 74 indexed citations

13.

Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2019). ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). 259–259. 153 indexed citations

14.

Qian, Yimin, Monica Andreoli, Mark Bookbinder, et al.. (2019). Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer. Cancer Research. 79(4_Supplement). P5–4. 106 indexed citations

15.

Cacace, Angela, John J. Flanagan, Michael Berlin, et al.. (2019). O5‐04‐05: A NEW THERAPEUTIC STRATEGY FOR TAUOPATHIES: DISCOVERY OF HIGHLY POTENT BRAIN PENETRANT PROTAC^TM DEGRADER MOLECULES THAT TARGET PATHOLOGIC TAU PROTEIN SPECIES. Alzheimer s & Dementia. 15(7S_Part_31). 2 indexed citations

16.

Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 381–381. 14 indexed citations

17.

Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer. Cancer Research. 78(13_Supplement). 5236–5236. 50 indexed citations

18.

Narang, Ajit S., Anand Balakrishnan, J. S. Morrison, et al.. (2017). Role of regional absorption and gastrointestinal motility on variability in oral absorption of a model drug. European Journal of Pharmaceutics and Biopharmaceutics. 117. 333–345. 5 indexed citations

19.

Kim, Sean, Joseph Dinchuk, Mary Zoeckler, et al.. (2009). Evaluation of Cynomolgus Monkey Pregnane X Receptor, Primary Hepatocyte, and in Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 Induction. Drug Metabolism and Disposition. 38(1). 16–24. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact